Study on effective prevention of chemotherapy-induced nausea and vomiting based on genetic polymorphism

Study on effective prevention of chemotherapy-induced nausea and vomiting based on genetic polymorphism - Clinical pharmacogenetics study for antiemetic therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000007135

Enrollment

180

Registered

2012-01-25

Start date

2011-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Breast cancer patients 2) Patients who receive the standard dose of AC combination 3) 20 years-old over at the time of giving informed consent 4) ECOG PS 0-2 5) Adequate organ function obtained within 2 weeks prior to registration. Laboratory values must be as follows; WBC >= 3000/mm3 PLT >= 100000/mm3 AST <= 100 IU/L ALT <= 100 IU/L T-Bill <= 2.0 mg/dL S-Cr <= 1.5 mg/dL 6)Informed consent by the document

Exclusion criteria

Exclusion criteria: 1) Known prior severe hypersensitivity to anthracyclines, cyclophosphamide, 5HT3 receptor antagonist, corticosteroids and NK-1 receptor antagonists 2) Patients who do not have enough whole body state to the antineoplastic agents treatment 3) Pregnant, breastfeeding or expecting woman 4) Patient with severe uncontrollable diabetes mellitus 5) Known symptomatic brain metastasis 6) Other clinical difficulties in this study

Design outcomes

Primary

Measure	Time frame
Proportion of complete response (defined as no emesis and no rescue treatment). [Time Frame: overall; 0-120hr(during and post chemotherapy), acute phase;0-24hr, delayed phase 24-120hr]	—

Countries

Japan

Contacts

Public ContactDaiki TSUJI

Univercity of Shizuoka School of Pharmaceutical Science

d-tsuji@u-shiuzoka-ken.ac.jp054-264-5674

Outcome results